Physician profile
Richard Stark
NPI 1023104049
$857.31
in general payments reported to CMS, 2019-2025
14 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $65.10 · 2023: $237 · 2024: $221 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $595.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $211.80 | 2019-2025 | |
| Novo Nordisk INC | $204.93 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Lilly USA, LLC | $73.00 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $72.35 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $57.06 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $48.92 | 2024-2025 | Rexulti |
| Dexcom, INC. | $43.50 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $32.42 | 2023 | Octrode |
| Averitas Pharma INC. | $29.66 | 2024 | Qutenza |
| Valeritas, INC. | $19.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.54 | 2019 | |
| Exact Sciences Corporation | $15.86 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $15.56 | 2019 | |
| Abbvie INC. | $13.90 | 2023 | Vraylar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.